Results 1 to 10 of about 765 (100)

Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for Mycobacterium abscessus lung disease [PDF]

Antimicrobial Agents and Chemotherapy
The guideline-based therapy achieves sputum culture conversion rates in 20%–34% of patients with Mycobacterium abscessus (MAB) lung disease (LD). Double-β-lactam combinations have been proposed to improve cure based on time-kill curves.
Sanjay Singh, Avneesh Shrivastava, Gunavanthi D. Boorgula, Mary C. Long, Brian Robbins, Pamela J. McShane, Tawanda Gumbo, Shashikant Srivastava   +7 more
doaj   +2 more sources

Consistent in vitro activity of sulbactam-durlobactam against genetically diverse carbapenem-resistant Acinetobacter baumannii in a high-endemic Brazilian setting [PDF]

Antimicrobial Agents and Chemotherapy
Carbapenem-resistant Acinetobacter baumannii (CRAb) causes high-mortality infections, with limited treatment options. We evaluated sulbactam-durlobactam activity against 94 isolates from Brazil.
Gabriela da Silva Collar, Luana Silva Dornelles, Júlia Cover Salvador, Jaqueline Becker Pinto, Dariane Castro Pereira, Patrícia Orlandi Barth, João Vitor Barboza Cardoso, William Latosinski Matos, Mariana Preussler Mott, Afonso Luís Barth, Andreza Francisco Martins, Juliana Caierão   +11 more
doaj   +2 more sources

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam

Frontiers in Microbiology, 2021
Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with broad spectrum activity against Ambler class A, C, and D serine β-lactamases.
Samir Moussa, Adam Shapiro, Alita Miller   +2 more
exaly   +3 more sources

A 4-methyl-substituted durlobactam analogue as a potential class-D oxacillinase inhibitor in Acinetobacter baumannii—an in silico study [PDF]

Frontiers in Bioinformatics
The emergence of extensively drug-resistant Acinetobacter baumannii expressing oxacillinases poses a significant challenge in nosocomial settings. Despite durlobactam being a potent β-lactam inhibitor, its long-term efficacy is limited, particularly ...
Elizabeth Annie George, Elizabeth Annie George, Aniket Naha, Sudha Ramaiah, Sudha Ramaiah   +4 more
doaj   +2 more sources

Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece

Frontiers in Cellular and Infection Microbiology, 2022
BackgroundAcinetobacter baumannii is a leading cause of healthcare-associated infections worldwide, due to both its persistence in the hospital setting and ability to acquire high levels of antibiotic resistance. Carbapenem-resistant A.
Maria Siopi, Spyros Pournaras
exaly   +3 more sources

Sulbactam–durlobactam and cefiderocol combination treatment of Burkholderia cenocepacia-associated Fitz–Hugh–Curtis syndrome [PDF]

Antimicrobial Agents and Chemotherapy
A 50-year-old woman with cystic fibrosis (CF) and lung transplantation developed persistent deep abscesses due to multidrug-resistant (MDR) Burkholderia cenocepacia, unresponsive to multiple antibiotics and surgeries.
Bhavita Gaglani, Tessa M. Andermann, Claire Wate, Jorge Oldan, Chirag S. Desai, Steven H. Marshall, Robert A. Bonomo, Ray Coakley, David van Duin, Anne Lachiewicz   +9 more
doaj   +2 more sources

Case Commentary: When susceptibility is not enough in recurrent Burkholderia cenocepacia infection [PDF]

Antimicrobial Agents and Chemotherapy
In this issue, B. Gaglani, T. M. Andermann, C. Wate, J. Oldan, et al. (Antimicrob Agents Chemother 70:e01542-25, 2026, https://doi.org/10.1128/aac.01542-25) describe a recurrent Burkholderia cenocepacia infection successfully treated with cefiderocol ...
Simone Giuliano, Paolo Gaibani, Carlo Tascini   +2 more
doaj   +2 more sources

Salvage Treatment of Ventilator-Associated Pneumonia Using Sulbactam–Durlobactam in a Preterm Neonate: A Case Report [PDF]

Infectious Disease Reports
Background: Ventilator-associated pneumonia (VAP) is a leading cause of nosocomial infections in neonatal intensive care units (NICUs) and is associated with significant morbidity, mortality, and prolonged hospitalization, particularly in preterm ...
Suzana Zivojinovic, Tijana Prodanovic, Nikola Prodanovic, Rasa Medovic, Milica Cekerevac, Dragana Savic, Bojana Markovic, Slobodan Jankovic   +7 more
doaj   +2 more sources

Antimicrobial activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex strains causing non-respiratory and non-bloodstream infections from the United States (2023–2025) [PDF]

Microbiology Spectrum
Acinetobacter baumannii most often causes pneumonia in critically ill patients. However, A. baumannii is also an important cause of a broader range of infections, including skin/wound and urinary tract infections. This study aims to evaluate the in vitro
Elizabeth Cyr, Jill Argotsinger, Eric T. Beck, Robin R. Chamberland, Andrew E. Clark, Anne R. Daniels, Rachael Liesman, Mark Fisher, Philip Gialanella, Jonathan Hand, Amanda T. Harrington, Romney M. Humphries, Holly Huse, Robert Hamilton-Seth, Julia D. Hankins, Wesley D. Kufel, Scott W. Riddell, Meera Mehta, Ryan Demkowicz, A. Brian Mochon, Hossein Salimnia, Ayesha Khan, Virginia M. Pierce, Raghava Potula, Tsigereda Tekle, Patricia J. Simner, Robert J. Tibbetts, Christine Vu, Lilian M. Abbo, Octavio Martinez, Rebekah E. Dumm, Manohar B. Mutnal, Timothy C. Jenkins, Violeta Chávez, Paulette Pinargote, Jennifer Bowling, Erik Munson, Daniel V. Zurawski, David P. Nicolau, Tomefa E. Asempa   +39 more
doaj   +2 more sources

Sulbactam–Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii: A Narrative Review [PDF]

Antibiotics
The increasing prevalence of infections caused by multidrug-resistant (MDR) Gram-negative bacteria represents a major global public health challenge.
Szymon Viscardi, Patrycja Lipska, Piotr Niezgódka, Anna Duda-Madej   +3 more
doaj   +2 more sources